Optimal background pharmacological therapy for heart failure patients in clinical trials: JACC review topic of the week

Fiuzat, M. et al. (2022) Optimal background pharmacological therapy for heart failure patients in clinical trials: JACC review topic of the week. Journal of the American College of Cardiology, 79(5), pp. 504-510. (doi: 10.1016/j.jacc.2021.11.033) (PMID:35115106)

Abstract

With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which novel therapies are studied. The Heart Failure Collaboratory convened a multistakeholder group of clinical investigators, clinicians, patients, government representatives including U.S. Food and Drug Administration and National Institutes of Health participants, payers, and industry in March 2021 to discuss whether standardization of background drug therapy is necessary in clinical trials in patients with HF. The current paper summarizes the discussion and provides potential conceptual approaches, with a focus on therapies indicated for HF with reduced ejection fraction.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: McMurray, Professor John
• Authors: Fiuzat, M., Hamo, C. E., Butler, J., Abraham, W. T., DeFilippis, E. M., Fonarow, G. C., Lindenfeld, J., Mentz, R. J., Psotka, M. A., Solomon, S. D., Teerlink, J. R., Vaduganathan, M., Vardeny, O., McMurray, J. J.V., and O’Connor, C. M.
• College/School: College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
• Journal Name: Journal of the American College of Cardiology
• Publisher: Elsevier
• ISSN: 0735-1097
• ISSN (Online): 1558-3597
• Published Online: 31 January 2022
• Copyright Holders: Copyright © 2022 The Authors
• First Published: First published in Journal of the American College of Cardiology 79(5):504-510
• Publisher Policy: Reproduced under a Creative Commons licence